Five Prime Therapeutics

Five Prime Therapeutics Newswire

Comprehensive Real-Time News Feed for Five Prime Therapeutics.

Results 1 - 20 of 115 in Five Prime Therapeutics

  1. Three Reasons Why The Bay Area Beats Other Biotech HubsRead the original story

    Yesterday | BioSpace

    BayBio, the longtime Northern California life sciences trade group, is in the final days before it merges with the California Healthcare Institute to give the biotech industry a bigger voice in Sacramento and Washington, D.C. But Gail Maderis, who shepherded the organization for more than five years after stepping down as CEO of Five Prime Therapeutics Inc., isn't backing down. With a figurative foam "We're #1" finger on her hand, in her final letter to BayBio members, Maderis shuns the "Top 10" lists and outlines why the Bay Area beats other regional biotech hubs.

    Comment?

  2. BayBio boss' goodbye: 3 reasons why the Bay Area beats other biotech hubsRead the original story w/Photo

    Yesterday | Business Journal

    BayBio, the longtime Northern California life sciences trade group, is in the final days before it merges with the California Healthcare Institute to give the biotech industry a bigger voice in Sacramento and Washington, D.C. But Gail Maderis, who shepherded the organization for more than five years after stepping down as CEO of Five Prime Therapeutics Inc., isn't backing down. With a figurative foam "We're #1" finger on her hand, in her final letter to BayBio members , Maderis shuns the "Top 10" lists and outlines why the Bay Area beats other regional biotech hubs.

    Comment?

  3. Scientists unveil map of 'epigenome,' a second genetic codeRead the original story w/Photo

    Wednesday Feb 18 | CNews

    Scientists for the first time have mapped out the molecular "switches" that can turn on or silence individual genes in the DNA in more than 100 types of human cells, an accomplishment that reveals the complexity of genetic information and the challenges of interpreting it. Researchers unveiled the map of the "epigenome" in the journal Nature on Wednesday, alongside nearly two dozen related papers.

    Comment?

  4. Beyond DNA: 'Second genetic code' that turns genes on and off mappedRead the original story w/Photo

    Wednesday Feb 18 | CBC News

    Linda Lewis, right, and Leora Eisen are identical twins who were featured in the documentary Two of a Kind, which examines the differences between identical twins. Many of those differences are due to the epigenome, a "second genetic code" of switches that turn genes on and off.

    Comment?

  5. Scientists Unveil Map of 'Epigenome,' a 2nd Genetic CodeRead the original story w/Photo

    Saturday Feb 14 | Voice of America

    A DNA double helix is seen in an undated artist's illustration released by the National Human Genome Research Institute. FILE - A DNA double helix is seen in an undated artist's illustration released by the National Human Genome Research Institute.

    Comment?

  6. Five Prime Therapeutics, Inc. To Present At The 2015 Global Healthcare ConferenceRead the original story

    Wednesday Feb 4 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11, 2015 at 8:25 AM Eastern Standard Time. The conference will take place at the Waldorf Astoria Hotel in New York City.

    Comment?

  7. 5 Things Bristol-Myers Squibb Co.'s Management Wants You to KnowRead the original story w/Photo

    Wednesday Feb 4 | The Motley Fool

    ... has been busy signing numerous research deals with partners including Celgene , Novartis , and Five Prime Therapeutics to bolster its immuno-oncology platform. This trend appears set to continue going forward. This coming blockbuster will make every

    Comment?

  8. Roche Says Swiss Franc's Surge May Erode Profit Growth This YearRead the original story

    Wednesday Jan 28 | The Washington Post

    Roche Holding AG, the world's largest seller of cancer drugs, said the Swiss franc's surge may strip 9 percentage points from growth in operating profit this year. The currency's strength will probably pare 6 percentage points from sales growth, based on the average exchange rate for January, Chief Financial Officer Alan Hippe said at a press conference in Basel today.

    Comment?

  9. Roche Sees Profit, Sales IncreasingRead the original story w/Photo

    Wednesday Jan 28 | Wall Street Journal

    Roche Holding AG posted a 16% drop in annual profit as the Swiss drug maker booked large impairments and restructured its debt, but the company said Wednesday it expects sales and profit to increase this year. Basel-based Roche said sales are expected to grow in low- to mid-single digits in 2015, when stripping out the effect of foreign-currency exchange rate fluctuations.

    Comment?

  10. Apple's Earnings Report Looks Optimistic: MunsterRead the original story w/Photo

    Tuesday Jan 27 | Bloomberg

    Jan. 27 -- Piper Jaffray's Gene Munster discusses Apple's fiscal first-quarter profit with Bloomberg's Cory Johnson on "Bloomberg West." Jan. 28 -- Cancer drug Kadcyla "will remain a very important growth driver," said Roche Holding AG Chief Executive Officer Severin Schwan in an interview with Manus Cranny on Bloomberg Television's "Countdown" from Basel.

    Comment?

  11. Roche misses forecasts as costs riseRead the original story w/Photo

    Tuesday Jan 27 | MarketWatch

    Swiss drug maker Roche Holding AG said Wednesday that its full-year net income fell 16% despite rising sales of its cancer treatments. Basel-based Roche said net income attributable to shareholders fell to 9.33 billion Swiss francs from 11.16 billion francs a year earlier, missing analysts' forecasts of 11.54 billion francs.

    Comment?

  12. Roche Profit Misses ForecastsRead the original story w/Photo

    Tuesday Jan 27 | Wall Street Journal

    Swiss drug maker Roche Holding AG said Wednesday that its full-year net income fell 16% despite rising sales of its cancer treatments. Basel-based Roche said net income attributable to shareholders fell to 9.33 billion Swiss francs from 11.16 billion francs a year earlier, missing analysts' forecasts of 11.54 billion francs.

    Comment?

  13. Zeltiq Aesthetics Inc (ZLTQ), Five Prime Therapeutics Inc (FPRX): Point72's Latest Bullish MovesRead the original story w/Photo

    Tuesday Jan 27 | Insider Monkey

    Steve Cohen 's Point72 Asset Management has made bullish moves into a pair of medical technology stocks. According to separate filings with the SEC, the fund has obtained 5.2% and 5.0% stakes in Zeltiq Aesthetics Inc and Five Prime Therapeutics Inc , respectively.

    Comment?

  14. Justin Sullivan/Getty Images For a few holdouts, Mass. still isn't biotech centerRead the original story w/Photo

    Jan 19, 2015 | Boston.com

    Genetech, headquartered in south San Francisco, does not plan to open a research and development facility in the Boston area. "We do deals with Boston companies.

    Comment?

  15. Jefferies Group Raises Five Prime Therapeutics Price Target to $32.00Read the original story

    Jan 16, 2015 | AmericanBankingNews.com

    ... analysts have also recently issued reports about the stock. Analysts at Zacks upgraded shares of Five Prime Therapeutics from a "neutral" rating to an "outperform" rating and set a $29.50 price target on the stock in a research note on Tuesday. ...

    Comment?

  16. J.P. Morgan: Five Prime Therapeutics, Inc. CEO Says Experimental Drug ...Read the original story w/Photo

    Jan 14, 2015 | BioSpace

    January 15, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor Clinical stage biotech Five Prime Therapeutics Inc intends to put its experimental drug FPA008 to work tackling six tumor types in clinical trials that combine it with Bristol-Myers Squibb 's Opdivo, its chief executive told audience members at the J.P. Morgan Healthcare Conference Thursday. That news initially pushed shares of the Bay Area biotech up in Thursday trading--more welcome news on a day when Five Prime saw its rating upgraded by several analysts and investor websites.

    Comment?

  17. Roche Holding acquiring majority stake in US firm Foundation MedicineRead the original story w/Photo

    Jan 12, 2015 | Big News Network.com

    Our eNewspaper network was founded in 2002 to provide stand-alone digital news sites tailored for the most searched-for locations for news. With a traditional newspaper format, more than 100 sites were established each with a newspaper-type name to cover the highest-ranked regions, countries, cities and states.

    Comment?

  18. Roche invests $1B in U.S. genomics firmRead the original story w/Photo

    Jan 12, 2015 | USA Today

    Shares of Foundation Medicine more than doubled in pre-market trading early Monday, when Roche Holding AG announced plans to purchase a majority stake in the Cambridge, Mass.-based genomics company. Roche said Roche invests $1B in U.S. genomics firm Shares of Foundation Medicine more than doubled in pre-market trading early Monday, when Roche Holding AG announced plans to purchase a majority stake in the Cambridge, Mass.-based genomics company.

    Comment?

  19. Roche to buy $1B stake in genomics companyRead the original story w/Photo

    Jan 12, 2015 | Salt Lake Tribune

    San Francisco a Roche Holding plans to pay more than $1 billion for a majority stake in Foundation Medicine Inc. to get access to genomic tests for screening tumors and to develop a new generation of treatments for fighting cancer. Roche will buy 5 million new shares of Cambridge, Mass.-based Foundation for $50 each and make an offer to purchase stock from existing investors for the same price to take its stake to as much as 56 percent, the companies said in a statement Monday.

    Comment?

  20. Switzerland's Roche Holding and AC Immune strike U.S. dealsRead the original story w/Photo

    Jan 12, 2015 | TheStreet.com

    Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

    Comment?